This information was originally presented at the NCCN 21^st Annual Conference: Advancing the Standard of Cancer Care™ held in Hollywood, Florida, from March 31 – April 2, 2016.

This information was originally presented at the NCCN 21^st Annual Conference: Advancing the Standard of Cancer Care™ held in Hollywood, Florida, from March 31 – April 2, 2016.

The 2015 NCCN Case Manager and Medical Director Program Live Webinar Series will consist of six webinars on the topics of melanoma, biomarkers, management of cancer in older patients with comorbidities, managing symptoms and reducing complications, and two sessions on less common and complex canc

The 2015 NCCN Case Manager and Medical Director Program Live Webinar Series will consist of six webinars on the topics of melanoma, biomarkers, management of cancer in older patients with comorbidities, managing symptoms and reducing complications, and two sessions on less common and complex canc

Join Chloe Atreya, MD, PhD and Alan P. Venook, MD from UCSF Helen Diller Family Comprehensive Cancer Center as they present their multidisciplinary expertise on a range of cases pertaining to metastatic colorectal cancer (mCRC).

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colorectal Cancer Screening provide recommendations for selecting individuals for colorectal cancer screening, and for evaluation and follow-up of colon polyps.

Join Chloe Atreya, MD, PhD and Alan P. Venook, MD from UCSF Helen Diller Family Comprehensive Cancer Center as they present their multidisciplinary expertise on a range of cases pertaining to metastatic colorectal cancer (mCRC).

The NCCN Guidelines for Rectal Cancer begin with the clinical presentation of the patient to the primary care physician or gastroenterologist and address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance, management of recurrent and metastatic

This information was originally presented at the NCCN 20th Annual Conference: Advancing the Standard of Cancer Care™ held in Hollywood, Florida.

In an era of personalized medicine, an increased effort is being made to identify patients likely to benefit from targeted therapy. By limiting treatment to selected patients, both unnecessary cost and toxicity may be avoided.